Ouro Medicines, a biotechnology company developing immune reset therapeutics for people living with chronic immune-mediated diseases, ...

Practice of medicine could fundamentally change with these types of therapies,” said CEO Jaideep Dudani, of T cell engagers ...

Ouro is planning to leverage T cell engagers to deplete B cells and “reset” the immune system to treat immune-mediated ...

T cell engagers are having a moment, much like antibody-drug conjugates have for the past two years. The cell-depleting ...

This is the largest-ever primary fundraise in the Indian diagnostics segment and the first private equity round for Neuberg ...

葛兰素史克（以下简称“GSK”）今日宣布其HIV暴露前预防长效药物艾普特®（卡替拉韦注射液）正式上市，用于有感染风险的成人和青少年（体重≥35kg）进行HIV-1暴露前预防（PrEP），以降低性传播感染HIV-1的风险，结合安全的性行为措施以达到更好的HIV-1 PrEP效果。 截至2025年1月，卡替拉韦长效方案是国内首个且唯一获中国国家药品监督管理局批准上市的用于HIV暴露前预防的长效注射针剂 ...

Armed with $115 million and a clinical-stage asset, another player is emerging in the increasingly crowded T cell engager ...

A major population proteomics study using UK Biobank patient samples backed by 14 pharma companies has launched today with ...

Find insight on Zydus Lifesciences, Biotech and more in the latest Market Talks covering the Health Care sector.

Shingrix in 2017 received US FDA approval to prevent shingles in adults aged 50 and older. Since 2021, it has been approved for use in immunocompromised patients aged 18 and up. GSK estimates around ...

1月10日，葛兰素史克（以下简称“GSK”）宣布其HIV暴露前预防长效药物艾普特（卡替拉韦注射液）正式上市，用于有感染风险的成人和青少年（体重≥35kg）进行HIV-1暴露前预防（PrEP），以降低性传播感染HIV-1的风险，结合安全的性行为措施以达到更好的HIV-1 PrEP效果。

Plus, readers’ letters, family notices, this week’s events guide, mart prices, Remember When and much more. All in this ...